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Maternal antibodies provide protection for the developing fetus. Transplacental transport of pathogenic autoantibodies might pose a risk for the developing fetus. The
transport of antibodies across the placenta to the fetal circulation occurs through the
neonatal Fc salvage receptor (FcRn). During gestation, maternal autoantibodies are
able to penetrate the embryonic brain before a functional intact blood–brain barrier
is established. Brain-reactive antibodies to the water channel protein aquaporin-4
(AQP4) are a hallmark finding in neuromyelitis optica (NMO), a neurological disease
that predominantly affects women, many of whom are of childbearing age. AQP4–
IgG mediate astrocytic injury in a complement-dependent fashion. Recent studies
suggest these antibodies contribute to impaired pregnancy outcome. The aim of the
study was to investigate the transplacental transport as well as FcRn binding of a
monoclonal AQP4–IgG cloned from an NMO patient (wild-type antibody) compared to
five different mutated Fc domain of this antibody containing single amino acid substitutions in the Fc region. All of the Fc-mutated antibodies lack complement-dependent
cytotoxicity. Four of the five Fc-mutated antibodies showed limited transplacental
transport in vivo. Three mutated Fc with impaired transplacental transport showed
persistent binding to rodent FcRn at pH 6 but also at pH 7.2, suggesting that limited
transplacental transport could be due to diminished release from FcRn. One mutated
Fc with modestly limited transplacental transport showed diminished binding to FcRn
at pH 6. This study suggests that mutated Fc with intact transplacental transport
may be used to study antibody effector functions and Fc with limited transport may
be used as a carrier to deliver therapies to pregnant woman, while sparing the developing fetus.
Keywords: maternal antibody, transplacental transport, FcRn, aquaporin-4 IgG, complement-dependent
cytotoxicity
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INTRODUCTION

demyelinating neurological disease that predominantly affects
the optic nerve, spinal cord, and brain. AQP4–IgG testing is
included as a diagnostic marker of the disease (20) and several
studies in rodent models have demonstrated its pathogenicity (21, 22). AQP4–IgG is thought to result in tissue damage
primarily through complement-dependent cytotoxicity (CDC),
but other effector mechanisms such as antibody dependent
cell-mediated cytotoxicity may also appear to play a role in the
disease (23, 24).
Recently, several case reports have suggested that AQP4–IgG
can have a negative impact on pregnancy outcomes (25); further
studies are needed to address this question. It is reported that
women with NMO and AQP4–IgG have a higher rate of miscarriages and suffer more often from preeclampsia (25). Whether
placental or fetal damage results from anti-AQP4 IgG exposure
and whether the mechanism of injury is complement dependent
is not known.
In this paper, we compared transplacental transport of a
human monoclonal AQP4–IgG1 antibody cloned from a patient
with NMO (22), and five variants containing different point
mutations in the Fc domain designed to reduce complement
activation. All the antibodies with mutated Fc were deficient in
CDC in vitro; however, they differed in their ability to cross the
placenta. At the time point when less transplacental transport
was observed, all of the antibodies were present in the blood
at similar concentrations. Yet, one mutated Fc with impaired
transplacental transport showed diminished binding to mouse
FcRn at pH 6, while the other three mutated Fc antibodies with
severely impaired transplacental transport showed enhanced
binding to FcRn at pH 7.2, suggesting that the antibodies are not
as efficiently released from FcRn.
This study emphasizes that single point mutations in the
Fc region can affect transplacental transport. Our findings are
important for the study of effector mechanisms by which maternal antibodies mediates fetal pathology. In addition, Fc variants
with altered transport might also provide clinical application.

Antibodies play an essential role in health. During development,
they have a crucial role in providing the fetus with passive protection against pathogens. The transfer of immunity from the mother
to the fetus is dominated by IgG transport across the placenta
(1). Maternal antibodies cross the placenta beginning around the
second trimester of the pregnancy (2). Under routine conditions,
the neonatal Fc salvage receptor (FcRn) regulates antibody halflife; during pregnancy it also mediates transcytosis of IgG from
the maternal to the fetal circulation (3). Following internalization
of IgG by pinocytosis, the binding of IgG antibodies to FcRn
occurs in acidic early endosomes at pH 6 (4, 5). While unbound
IgG is degraded, FcRn–IgG complexes are routed away from the
lysosomal pathway and intact IgG is released at physiological pH
7.2 when phagolysosome fuses with the plasma membrane (6–9).
Therefore, both IgG binding to FcRn as well as its release from
FcRn can influence transplacental transport of antibodies.
Maternal IgG has a protective role during pregnancy, yet
pathogenic autoantibodies are also transported to the fetus and
may impair fetal development, resulting in either transient or
permanent damage to the developing fetus. The severity of the
insult is determined by several factors, such as the antigenic
specificity of the autoantibodies, maternal IgG concentration,
and the gestational stage at which the antigen is expressed.
It is well appreciated that a number of neonatal disorders are
associated with in utero exposure to pathogenic autoantibodies.
For example, transport of anti-acetylcholine receptor antibodies
from mothers with myasthenia gravis can result in either transient myasthenia gravis or in permanent defects in the neonate
(10–12) and transplacental transport of anti-Ro antibodies in
mothers with autoimmune disorders can result in fetal heart
block or neonatal lupus (13).
Pathogenic autoantibodies are not solely present in individuals with autoimmune diseases; they are also present in a subgroup
of healthy individuals. In fact, mothers of children with autism
spectrum disorder have an increased frequency of brain-reactive
antibodies (14), and in utero exposure to brain-reactive antibody
such as antibody to the neuronal voltage-gated potassium channel Caspr2, results in neurodevelopmental impairment and
permanent behavioral alterations in mice (15). Since the fetal
blood–brain barrier (BBB) is permeable to maternal IgG in mice
until gestational day E16.5 (16), and in humans most likely until
the third trimester, the developing brain is a potential target for
maternal autoantibodies, even when the mother experiences no
clinical symptoms.
Studies of the pathogenicity of maternal brain-reactive antibodies often employ a model in which the antibodies are injected
into a pregnant animal at a gestational stage when the antigen of
interest is expressed and the embryonic BBB allows penetration
of the antibody to the fetal brain (15, 17–19). Antibodies with
Fc mutations that alter effector function need to be analyzed for
transplacental transport in order to determine whether they can
be used in studies to address the mechanism of action of maternal
antibodies.
Here, we describe a brain-reactive antibody directed to AQP4
(AQP4–IgG). Neuromyelitis optica (NMO) is an inflammatory,
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MATERIALS AND METHODS
Human Monoclonal Antibodies

Human monoclonal AQP4–IgG (rAb-53) was cloned from a
plasmablast recovered from the cerebrospinal fluid of an NMO
patient, produced, and purified as previously described (22).
Isotype control (Ctl) was a non-brain binding antibody directed
against measles virus (2B4-IgG) (22). Recombinant human
AQP4–IgG (rAb-53) with mutated Fc sequences was generated by
site directed mutagenesis. Mutation nomenclature is according to
the EU index as described in Kabat et al. (26) K322A (KA) (27, 28),
P329A (PA) (28), N297D (ND) (29), D270A (DA) (28), and
P331G (PG) (28).

Cell-Based Assay (Immunofluorescence)

To confirm binding of wild-type and Fc-mutated antibodies to
AQP4, we performed a live cell-based assay as previously des
cribed (30) with some modifications. Briefly, human embryonic
kidney cells, HEK293T/17 (ATCC), were cultured on poly-d
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lysine (Sigma) coated glass cover slips (TED PELLA, Inc.) in
24-well plate. 24 h after seeding the cells, HEK293T/17 cells
were transiently transfected using FuGene (ProMega) with
AQP4 (M23 isoform) fused at its C terminus to an emerald
green fluorescent protein. Two days after transfection the assay
was performed.
Antibodies (Ctl-IgG, AQP4-IgG, DA-IgG, KA-IgG, ND-IgG,
PA-IgG, and PG-IgG), 5 µg/ml, were diluted in HBSS/10% FBS
and incubated with cells for 1 hour at 4°C. Cells were washed
three times with HBSS/10% FBS and incubated with a secondary anti-human antibody Alexa 594 (Invitrogen) for 30 min at
room temperature. Cells were washed three times, fixed with 4%
paraformaldehyde (PFA) for 15 min, washed again with HBSS
and coverslips were mounted on a slide. Pictures were acquired at
20× magnification using Axio-Imager Z-1 software (Axio-Vision,
Zeiss, Oberkochen, Germany). Untransfected cells served as
control. DAPI positive cells, i.e., dead cells, were excluded from
analysis.

all antibodies. The infrared labeled monoclonal antibody Ctl-IgG
which does not bind AQP4, was used as control for background
binding. Untransfected cells were used as controls.

Study Approval

All animal experiments were performed in accordance with
the National Institutes of Health Guidelines under protocols
reviewed and approved by the Institutional Animal Care and
Use Committee of the Feinstein Institute for Medical Research,
Northwell Health, Manhasset, NY, USA.

Mice and Injection of Infrared Labeled
Antibody

C57BL/6 mice (6–8 weeks old) were obtained from the Jackson
Laboratory. For timed pregnancy, 2 female mice and 1 male
mouse were housed together for 14 h. The time when the male
mouse was removed from the cage was designated embryonic (E)
day 0.5. Infrared labeled IgG (60 µg) was administered by retroorbital injection in 200 µl volume (300 µg/ml) to time-pregnant
mice under light anesthesia at E14.5. Embryos were harvested at
E15.5 as described below. The degree of transplacental transport
was at least confirmed for 2 litters to each antibody.

Infrared Labeling of Human Monoclonal
Antibodies

All human monoclonal antibodies were labeled with the IRDye
800 CW protein labeling kit following the manufacturer’s instructions (Microscale, Invitrogen). Briefly, the pH level was adjusted
to 8.5 by adding 1 M potassium phosphate buffer to 200 µl of
antibody solution (1 mg/ml of IgG in PBS). 1.4 µl of dissolved
dye was added to the antibody solution and the mixture was
incubated for 2 h at room temperature. Subsequently, free dye
was removed using Zeba Spin Desalting columns according to the
manufacturer’s instructions. Centrifuge columns were washed in
PBS three times, and excess wash solution was removed by dry
spin at 1,500 g. The columns were placed in a new collection tube
and 100 µl of the sample was applied to each column. The tube
was centrifuged at 1,500 g for 2 min to collect the sample. Integrity
of labeled antibodies was confirmed using a non-reducing 12%
Bis-Tris Protein Gel (NuPage, Invitrogen) according to manufacturer’s instruction. Gel was stained with Coomassie Brilliant Blue
Staining (Invitrogen).
To confirm intensity of labeling, dot blots were performed
with serial dilutions of infrared labeled antibodies, on a nitrocellulose membrane (Biorad, 0.45 µm), drying the membrane and
scanning for signal intensity. Starting dilution was 20 µg/ml of
infrared labeled antibody. Membrane analysis was performed
using the Odysey infrared imaging system (LICOR).

Infrared Scanning of Embryos

24 h after injection of the infrared labeled antibodies (Ctl-IgG,
AQP4-IgG, DA-IgG, KA-IgG, ND-IgG, PA-IgG, and PG-IgG) we
harvested the embryos with placenta attached and scanned the
embryo and placenta. An embryo not exposed to an antibody
was included as an additional control to confirm absence of
an infrared signal. Scan setting was kept constant for all litters.
Infrared signal intensity was quantified for each embryo using the
Odyssey Infrared Imaging System (LI-COR, Linconln, NE, USA)
and data are presented as ratio of pixel intensity of each embryo
normalized to the average pixel intensity of an AQP4 litter run
on the same scan to account for variability within scans. Embryos
were derived from 2 litters for each antibody.

Antibody Half-Life in Serum of Mice

10–20 µg of human IgG (Ctl-IgG, AQP4-IgG, KA-IgG, ND-IgG,
PA-IgG, and PG-IgG, noninfrared labeled) was injected retroribitally to non-pregnant female C57BL/6 mice (6–8 weeks old). To
determine levels of human IgG in the serum, mice were euthanized at indicated time points, and blood was collected through
the orbital sinus. Blood was spun down at 10,000 g for 15 min
and serum was removed and frozen at −20°C until use. Three
animals were analyzed for each antibody and blood was drawn
at different time points (time 0; 3 min after injection, time 0.5, 1,
2, 4, 6, 24, 48, and 72 h). Serum concentration of human IgG is
presented (μg/ml). Human IgG levels were measured by ELISA
as described below and presented as percentage of human IgG at
24 h relative to time 0.

Cell-Based Assay (for Infrared Labeled
Antibodies)

Binding to HEK 293 cells expressing AQP4 was confirmed by
cell-based assay as follows using HEK 293T/17 cells expressing AQP4 seeded in a 96-well tissue culture plate as previously
described (30). In short, cells were incubated with the infrared
labeled antibodies (1 µg/ml) in triplicates and incubated for
1 h at 4 C°. Following three washing steps with PBS/10% FBS,
the liquid was removed and the plate was immediately scanned
using an infrared imaging system (Odyssey-Licor). The signal
intensity of transfected and untransfected cells was compared for
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ELISA for Measuring IgG Concentrations

We used an ELISA to measure human IgG concentrations prior
to injections and at different time points after injection in the
serum of mice.
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ELISA plates (Costar) were coated with goat anti-human IgG
using a concentration of 10 µg/ml and incubated for 1 h at 37°C.
The plates were washed two times with PBS/Tween and subsequently blocked with PBS/3% FBS for an hour at 37°C. Following
two washing steps with PBS/Tween, samples were diluted in
PBS/0.3% FBS and incubated at 37°C for 90 min. Human corresponding IgG (Ctl-IgG, AQP4-IgG, DA-IgG, KA-IgG, ND-IgG,
PA-IgG, and PG-IgG) diluted to 200, 100, 50, 25, 12.5, 6.25, 3.125,
and 1.56 ng/ml was added as a standard. Following four washing
steps with PBS/Tween AP-conjugated secondary goat anti-human
IgG antibody (1:1,000 dilution) was added for 1 h at 37°C. Plates
were washed four times with PBS/Tween. Phosphatase developing
solution was added and plates were read at 405 nm absorbance
every 10 min. Concentration of each antibody prior to injection
was also confirmed using nanodrop.

The experiments at neutral pH were performed as described
above except that PBS pH 7.2 was used for FcRn dilution, association, and dissociation.
All data were referenced with individual AQP4 wild-type
or mutated Fc antibodies loaded biosensors incubated in assay
buffer instead of FcRn, and with the biosensor loaded with only
dilutant and various concentrations of FcRn. The sensorgrams
were plotted and evaluated using data analysis software version
9.0 (PALL/ForteBio). Rmax, the maximum response determined from the fit of the binding data and Req, the calculated
response at equilibrium that is determined from a fit of the
binding data are presented. In addition, KD (M) and KD error
are presented.

Statistical Analysis

We performed ANOVA followed by Dunnett’s multiple comparisons test as well as Student’s t-test for datasets that were normally
distributed. Otherwise, we performed Mann–Whitney test. All
tests were performed with the Graph pad prism statistical software package. Values were considered significant for p < 0.05.
Data are presented as mean and error bars represent standard
error. All tests were two tailed.

Complement-Dependent Cytotoxicity

Complement-dependent cytotoxicity assay was performed as
previously described (24). CHO cells stably expressing M23–
AQP4 were plated at 37,500 cells/well and cultured overnight
in CHO cell medium (10% FBS + 1% penicillin/streptomycin/
amphotericin B in F12 media; Gibco). Cells were washed twice
with pre-warmed F12 medium and incubated at 37°C for 60 min
with medium alone, 5% pooled human serum (Complement
Technology, Inc.), or Ab ± 5% pooled human serum. All Ab
treatments were at 5 µg/ml and were chosen based on a titration curve previously performed (24). Cells were then washed in
medium and treated for 15 min with 1 µM Calcein AM (CaAM;
Invitrogen) to label live cells green and 1 µM propidium iodide
(PI; Invitrogen) to label dead cells red. Images were taken on a
Leica inverted fluorescence microscope. Cells were counted using
ImageJ and the percentage of cell lysis was calculated as [PI positive cells/(PI positive + CaAM positive cells)] × 100%. Statistical
analysis was performed using analysis of variance (ANOVA) and
Dunnett’s test for multiple comparisons in GraphPad Prism 5
software.

RESULTS
Binding to AQP4

Five Fc-mutated antibodies of an IgG1 anti-AQP4 antibody
were generated, all with an identical light chain and heavy chain
variable region, but each with a single amino acid substitution in
the Fc region of the heavy chain. All Fc-mutated antibodies were
tested for AQP4 binding. As seen in Figure 1, all mutated AQP4
antibodies bound to AQP4 in a live cell assay.

Complement Activation

The mutations in the Fc region were designed to decrease
CDC. We determined that each Fc-mutated antibody displayed altered complement activation compared to wild-type
AQP4–IgG using an in vitro assay. The wild-type AQP4–IgG
antibody activated complement as previously described (27).
Each of the five Fc-mutated antibodies lacked the ability to
activate the complement cascade, and exhibited diminished
CDC (Figures 2A,B).
No cell lysis was observed with wild-type AQP4-IgG in the
absence of human complement, or with isotype-matched Ctl-IgG
antibody or medium containing human complement alone
(Figure 2B; Table 1).

FcRn Binding Using Octet Fortebio

FcRn binding experiments were performed on an Octet K2 (PALL/
ForteBio) instrument at 30°C, according to ForteBio technical
note 19 and 34 (https://www.fortebio.com/literature.html). To
measure FcRn binding, human monoclonal antibodies that were
not infrared labeled were used and each antibody was analyzed
using three independent times at two different pH levels, showing comparable results. Anti-human Fab-CH1 biosensors (PALL
ForteBio) were loaded with monoclonal antibodies (6 µg/ml) in
kinetic buffer (PALL ForteBio). The concentration of antibody
was selected by an optimization step as described in technical
note 19.
For association phase, mouse FcRn-Beta-2 microglobulin
heterodimer protein (ImmuniTrack) was diluted with assay association and disassociation buffer (100 mM sodium phosphate,
150 mM Nacl, 0.05% Tween-20, pH 6) to concentrations ranging
from 2,000 to 0 nM and transferred to solid-black 96-well plate
(Greiner Bio-One). FcRn was allowed to bind to IgG loaded
biosensors for 60 s. The dissociation phase was recorded in assay
buffer pH 6.0 for 60 s.

Frontiers in Immunology | www.frontiersin.org

Transplacental Transport of Antibodies

In order to investigate transplacental transport of AQP4–IgG
and the five CDC Fc-mutated antibodies, we injected infrared
labeled antibody intravenously into pregnant mice. Antibody was
administrated by retro-orbital injection into pregnant dams on
embryonic day E14.5 and fetuses were scanned for the presence
of the infrared labeled antibody 24 h later, a time point when the
embryonic BBB still allows antibody transport to the brain (16)
(Figures 3 and 4; Figure S1 in Supplementary Material). Embryos
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Reduced transplacental transport could not be explained
by a difference in labeling of the antibodies or differences in
binding to AQP4, since we confirmed that all antibodies had
the same degree of labeling prior to injection (Figures S3A,B in
Supplementary Material), and we confirmed that labeling had
no effect on their ability to bind to AQP4 expressed by transfected HEK293T cells (Figure 1; Figure S4 in Supplementary
Material). Integrity of the labeled antibodies was confirmed
with non-reducing SDS Page (Figure S3C in Supplementary
Material).
The difference in the maternal-fetal transport of infrared
labeled antibody was not associated with different antibody
concentrations in the blood at the time point when the transplacental transport was performed (Figure S5A in Supplementary
Material). Only the DA-IgG antibody showed some trend to
reduced concentration at 24 h (Figure S5B in Supplementary
Material).

Effect of Mutation on FcRn Binding

Because the function of FcRn involves IgG binding at pH 6, and
antibody release at pH 7.2, we assessed all antibodies for pHdependent binding to mouse FcRn.
As shown in Table 2 and Figure 5A and Figure S6 in Supple
mentary Material all antibodies except Fc-mutated DA-IgG
showed comparable binding to mouse FcRn at pH 6. Rmax and
Req, but not KD values of DA-IgG indicated reduced binding to
FcRn at pH 6 compared to the wild-type AQP4 antibody.
As expected, all antibodies bound less well to mouse FcRn
(2 µM) at pH 7.2 compared to pH 6 (Figure 5B). The three
Fc-mutated antibodies with the most impaired transplacental
transport (KA-IgG, ND-IgG, and PG-IgG) demonstrated elevated
binding to FcRn at pH 7.2, compared to the wild-type AQP4–IgG,
PA-IgG, and DA-IgG.

DISCUSSION
Figure 1 | Cell-based assay demonstrating binding of AQP4–IgG and
Fc-mutated AQP4–IgG to AQP4 transfected cells. Binding of infrared labeled
AQP4–IgG and all Fc-mutated antibodies DA-IgG, KA-IgG, PA-IgG, and
PG-IgG (shown in red) to HEK cells which express AQP4 fused with a green
fluorescent protein (shown in green). The mutations do not interfere with the
ability of the antibodies to bind AQP4. The isotype Ctl-IgG, does not bind to
AQP4 transfected cells. None of the antibodies bind to non transfected cells
(not shown).

Maternal IgG is transferred to the fetus during pregnancy by
binding to FcRn. In mice, access to the fetal brain is possible until
around embryonic day E16.5 (16). Studies have indicated the
possibility that AQP4 antibodies present within the circulation
of a mother with NMO might also affect the offspring (25, 31), as
has been shown for some other brain-reactive antibodies (15, 32).
AQP4 antibodies act primarily through CDC to induce pathology
in NMOSD patients (23).
In our study, we evaluated the transplacental transport of five
Fc-mutated AQP4–IgG antibodies which lack complement activation using a well-established method as previously described
(16, 17, 32).
Interestingly, we observed that four out of five antibodies
containing point mutations in the Fc portion that diminish CDC
effector function had impaired penetration to the fetus when
injected into a pregnant dam at embryonic day E14.5.
It is known that FcRn binding is required for transport of IgG
across the placenta in mouse and human. Altering a single amino
acid in the Fc region of IgG can affect placental transport of IgG,
through affecting the binding to FcRn (33). Crystal structure
analysis as well as site-directed mutagenesis have provided some

derived from two litters from each antibody were compared to
the transport of wild-type AQP4–IgG (Figure 4; Figure S1 in
Supplementary Material). Whereas Ctl-IgG antibody, wild-type
AQP4-IgG antibody and the Fc-mutated antibody PA-IgG
showed equal transport to the fetus, four Fc-mutated antibodies
exhibited reduced fetal transport; the impact ranged from modest
(DA-IgG) to severe (KA-IgG, ND-IgG, and PG-IgG) (Figures 3
and 4; Figure S1 in Supplementary Material). The antibodies that
entered the fetal circulation could all be observed in the fetal
brain. Placentas showed similar levels of high infrared signal
even for mutated antibodies with less transplacental transport,
as shown for Fc-mutated ND-IgG in Figure S2 in Supplementary
Material.

Frontiers in Immunology | www.frontiersin.org
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Figure 2 | Antibody Fc domain mutations limit complement-dependent cytotoxicity activation by AQP4–IgG. (A) CHO cells expressing M23–AQP4 were incubated
with 5 µg/ml monoclonal antibody in the absence (left row) or presence (right row) of 5% pooled human serum (hC) for 60 min at 37°C. Live cells are labeled with
calcein AM, which is a cell viability dye (green); dead cells are labeled with propidium iodide (red). (B) Cell lysis (mean percentage ± SD) is plotted for medium alone,
hC alone, and each monoclonal antibody without (top) or with (bottom) hC. Ctl-IgG is specific for measles virus nucleocapsid protein and serves as a negative
control. *p < 0.0001; analysis of variance with Dunnett’s multiple comparisons test.

close proximity to the FcRn binding site (34–36), therefore,
altering those amino acids might result in altered FcRn binding.
Indeed, it has been shown that the histidine residues H310 and
H435 are critical for the pH-dependent binding of IgG to FcRn
(34–36). Mutations at these residues lead to decreased binding at
pH 6.
In our study the substitution DA led to, although significant,
only a modest reduction of transplacental transport, which could
be attributed to its reduced ability to bind FcRn at pH 6, as indicated by reduced Rmax and Req values, and a trend to reduced
concentration in the blood 24 h after injection.
The Fc-mutated ND-IgG, KA-IgG, and PG-IgG had substantially
diminished transplacental transport compared to AQP4–IgG1. In
contrast to DA-IgG, these antibodies showed intact FcRn binding
at pH 6; however, all exhibited slightly enhanced FcRn binding at
pH 7.2, likely resulting in a failure to be as efficiently released as
wild-type AQP4-IgG from FcRn engagement at the fetal site of
the placenta, which could provide one possible explanation for
limited transport.
While previous studies have shown that the mutations KA
and DA and P331A (but not P331G) do not affect human
FcRn binding at pH 6, and PA and N297A (but not N297D)
have slightly reduced affinity at pH 6 (37), we are not aware of
literature testing human IgG1 at pH 6 and pH 7.2 with those
mutations for binding to mouse FcRn. Asparagine 297 is a

Table 1 | AQP4–IgG-mutated antibodies with limited complement-mediated
cytotoxicity.
Treatment
Medium
5% hC
Ctl-IgG
Ctl-IgG + 5% hC
AQP4-IgG
AQP4-IgG + 5% hC
PA-IgG
PA-IgG + 5% hC
DA-IgG
DA-IgG + 5% hC
PG-IgG
PG-IgG + 5% hC
KA-IgG
KA-IgG + 5% hC
ND-IgG
ND-IgG + 5% hC

% Lysis (mean ± SD)
0.00 ± 0.00
0.00 ± 0.00
0.24 ± 0.14
0.36 ± 0.36
0.31 ± 0.31
48.39 ± 0.97
0.11 ± 0.11
0.82 ± 0.34
0.11 ± 0.11
3.89 ± 1.87
0.00 ± 0.00
2.23 ± 0.87
1.38 ± 0.86
1.07 ± 0.28
0.00 ± 0.00
2.05 ± 1.62

Cell lysis of CHO cells expressing AQP4 (mean percentage ± SD) is presented for
medium alone, human complement (hC) alone, and Ab without (top) or with (bottom)
hC. Ctl-IgG antibody is specific for measles virus nucleocapsid protein and serves as a
negative control. *p < 0.001, analysis of variance with Dunnett’s multiple comparison test.

information regarding the FcRn/IgG interaction sites. Particularly,
amino acid residues at position 252–256 in the CH2 domain and
positions 310, 433, 434, and 435 in the CH3 domain are at or in
Frontiers in Immunology | www.frontiersin.org
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Figure 3 | Effect of mutations of AQP4–IgG on transport across the placenta. Infrared labeled AQP4–IgG and its isotype control antibody (Ctl-IgG) as well as the
Fc-mutated PA-IgG show an equal degree of transplacental transport in the embryo (A). DA-IgG shows modestly diminished transport (B). KA-IgG, ND-IgG, and
PG-IgG have severely impaired transplacental transport (C). Each antibody was tested in 2 litters at a concentration of 60 µg.

Table 2 | Binding of antibodies to mouse FcRn.

Ctl-IgG
AQP4-IgG
PA-IgG
DA-IgG
PG-IgG
KA-IgG
ND-IgG

pH 7.2

pH 6

pH 7.2

Req
0.76
0.8505
1.1556
0.43
0.915
0.9868
1.0028

Req
0.03
0.0948
0.0365
0.0482
0.1512
0.198
0.1355

Rmax
0.82
0.9599
1.2766
0.45
0.9796
1.119
1.1174

Rmax
0.128
0.1043
0.0365
0.042
0.2728
0.4056
0.2152

Binding of antibodies to mouse FcRn at an IgG concentration of 6 µg/ml. Binding is
shown at equilibrium response Req or as the maximum binding signal Rmax. Binding was
tested at pH 6 and pH 7.2. All antibodies show equal binding at pH 6, except antibody
DA-IgG, which has lower binding. Antibodies with enhanced binding at pH 7.2 (NDIgG, PG-IgG, and KA-IgG) are shown in bold. Experiments were performed three times
for each antibody at pH 6 and pH 7.2 and representatives are shown for each antibody.

Figure 4 | Quantification of transplacental transport of antibodies.
Quanitification of optical intensity of the infrared signal (pixel intensity) from
embryos exposed to maternal infrared labeled antibodies in utero. The values of
each embryo is averaged and shown normalized to the average pixel intensity of
an AQP4–IgG exposed litter present on the same scan to account for variability
within scans (normalized pixel intensity). Transplacental transport of each
antibody is shown for both litters. One-Way analysis of variance followed by
Dunnett’s multiple comparisons test revealed that mice injected with PG-IgG,
KA-IgG, and ND-IgG showed markedly reduced normalized infrared pixel
intensity compared to AQP4–IgG (**p < 0.0001). DA-IgG showed a modest, but
significant reduction, infrared pixel intensity compared to AQP4–IgG (*p < 0.005).
Ctl-IgG, AQP4-IgG, and PA-IgG are not different (p > 0.8).
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pH 6

glycosylation site (38), however, there are controversial data
regarding the effect of altered glycosylation on the transplacental transport (39, 40). Moreover, a previous study has shown
that human IgG1 has a different affinity for mouse compared to
human FcRn (41).
Little information is available to explain the lack of transplacental transport of antibodies with intact binding to FcRn. A mutated
antibody with a IgG3ΔHinge mutation failed to cross the placenta
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Figure 5 | Antibodies binding to mouse FcRn. ForteBio kinetic. Ctl-IgG and AQP4–IgG and Fc-mutated antibodies (6 µg/ml) were loaded to the sensors. The sensors
were exposed to 2 nM FcRn solution for association (0–60 s) and for dissociation solution (60–120 s). Sensorgrams showing the association and dissociation steps.
(A) pH 6 and (B) pH 7.2. See Table 2 for Rmax and Req of all antibodies. Each antibody was analyzed three independent times and representatives are shown.

in a placenta perfusion model but this was not related to a lack of
human FcRn binding (33).
It also appears that other Fc receptors might be involved in
transplacental transport of IgG. Evidence for a contribution of
additional receptors comes from human studies. In humans,
FcγRIIb is expressed by placental villous endothelial cells, and
is believed to play a role in transporting IgG across the villous
endothelium. In mice, FcγRIIb has been shown to mediate IgG
endocytosis and transcytosis in vitro, and is expressed in the
placenta yolk sac vasculature, and thus could function as an
additional IgG transporter (42). However, it is not clear whether
this receptor is critical to transport IgG across the placenta, since
fetuses of mice lacking FcγRIIb show comparable levels of IgG as
wild-type mice (43).
Transport of IgG from mother to fetus can also be used for
therapeutic ends by fusing the therapeutic protein to an Fc
fragment. Grubb and colleagues administered β-glucuronidase
(GUS) fused to an Fc region to pregnant mice in order to reverse
GUS deficiency in a mouse model of mucopolysaccharidosis (44). It is also possible to envision the use of IgG with an
altered Fc region to generate a therapeutic agent that will not
be transported to the fetus and, therefore, will not endanger the
developing fetus.
We would like to hypothesize that fusing antigen to a mutated
Fc region that does not cross the placenta but has a reasonable
half-life might serve as a novel therapeutic strategy in pregnant
mothers, to prevent the transport of pathogenic IgG to the fetus.
Fc can improve solubility, stability, and half-life of the fused molecule, and as in this study, can be manipulated to have reduced
CDC or other effector mechanisms. Therefore, administrating a
fusion protein consisting of antigen and mutated Fc during pregnancy to absorb pathogenic antibody could theoretically remove
pathogenic antibody within the mother without affecting the
developing fetus. Since immune complexes are not transported to
the fetus, we speculate that the Fc fusion protein will be removed
by the reticuloendothelial system in the mother or the placenta.
This strategy is currently being studied. This therapeutic strategy
could be used to supply decoy antigen not only for AQP4–IgG but

Frontiers in Immunology | www.frontiersin.org

also for other antibody mediated diseases, where the presence of
antigen-specific antibodies during pregnancy can adversely affect
the developing fetus.
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